Evaluation of the Effectiveness of Three Tear Substitute Formulations in Postoperative Discomfort After Cataract Surgery

NCT07581548 — Not yet recruiting, 300 participants, Democritus University of Thrace

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Evaluation of the Effectiveness of Three Tear Substitute Formulations in Postoperative Discomfort After Cataract Surgery: A Non- Interventional, Observational Study

RegistryNCT07581548, acronym DRY-CAT
StatusNot yet recruiting
Study typeObservational
Enrollment300 (Estimated)
SponsorDemocritus University of Thrace (Other)
ConditionsCataract, Dry Eye
InterventionsSodium Hyaluronate 0.15% and Dexpanthenol 2% drops (Hylopan max), Sodium Hyaluronate 0.15% and Trehalose 3% drops (Thealoz duo), Sodium Hyaluronate 0.2% and Amino acids drops (Helenvision ultra) (Drug)
Datesstart 2026-05-01 (estimated), primary completion 2026-12-31 (estimated), completion 2027-05-01 (estimated), first posted 2026-05-12, last updated 2026-05-12
Locations1 site in Greece

Related Papers Related Patents Related Grants Related Experts
All trials for Cataract All trials for Dry Eye All trials of Sodium Hyaluronate 0.15% and Dexpanthenol 2% drops (Hylopan max) All trials of Sodium Hyaluronate 0.15% and Trehalose 3% drops (Thealoz duo)

-Summary

The primary objective of this study is the assessment of three tear substitute formulations in terms of postoperative discomfort following cataract extraction surgery by means of phacoemulsification and intraocular lens implantation.

Expand all sections  ·  Collapse all

+Detailed description

Participants will be recruited from the Cataract Service of the University Hospital of Alexandroupolis (UHA). All participants will be randomly assigned to three study groups. Study group 1 will receive a fixed combination of chloramphenicol and dexamethasone (Dexachlor, Cooper, Greece) quid for 4 weeks and 0.15 % sodium hyaluronate \& Dexpanthenol 2% (Hylopan max, Zwitter, Greece) quid for 12 weeks. Study group 2 will receive a fixed combination of chloramphenicol and dexamethasone (Dexachlor, Cooper, Greece) quid for 4 weeks and 0.15 % sodium hyaluronate \& Trehalose 3% (Thealoz duo, Thea, Greece) quid for 12 weeks. Study group 3 will receive a fixed combination of chloramphenicol and dexamethasone (Dexachlor, Cooper, Greece) quid for 4 weeks and 0.2% sodium hyaluronate and amino acids (Helenvision Ultra, Pharmex, Greece) quid for 12 weeks.

+Arms and interventions

ArmTypeInterventionsDescription
Study Group 1Drug: Sodium Hyaluronate 0.15% and Dexpanthenol 2% drops (Hylopan max)Sodium Hyaluronate 0.15% and Dexpanthenol 2% drops (Hylopan max)
Study Group 2Drug: Sodium Hyaluronate 0.15% and Trehalose 3% drops (Thealoz duo)Sodium Hyaluronate 0.15% and Trehalose 3% drops (Thealoz duo)
Study Group 3Drug: Sodium Hyaluronate 0.2% and Amino acids drops (Helenvision ultra)Sodium Hyaluronate 0.2% and Amino acids drops (Helenvision ultra)
  • Sodium Hyaluronate 0.15% and Dexpanthenol 2% drops (Hylopan max) (Drug): Cataract patients will be administered Drops of Sodium Hyaluronate 0.15% and Dexpanthenol 2% quid in their postoperative regimen
  • Sodium Hyaluronate 0.15% and Trehalose 3% drops (Thealoz duo) (Drug): Cataract patients will be administered Drops of Sodium Hyaluronate 0.15% and Trehalose 3% quid in their postoperative regimen
  • Sodium Hyaluronate 0.2% and Amino acids drops (Helenvision ultra) (Drug): Cataract patients will be administered Drops of Sodium Hyaluronate 0.2% and Amino acids quid in their postoperative regimen

+Outcome measures

Primary outcomes

  • Ocular Surface Disease Index (OSDI) [12 weeks]: A subjective parameter that quantifies corneal discomfort
  • Tear Break-up Time (TBUT) [12 weeks]: An objective parameter that quantifies stability of tear film

Secondary outcomes

  • Schirmer test (basal tear production) [12 weeks]: An objective test that assesses basal tear production alone using topical anesthetic drops, by removing the stimulus that triggers reflex tearing.
  • Efron scale for bulbar redness [12 weeks]: A clinical tool consisting of five photographic, color-calibrated images (graded 0 to 4) that allow practitioners to classify the severity of conjunctival hyperaemia, ranging from normal to severe Grade 0: Normal, pale eyelid margin, minimal conjunctival vessels. Grade 1: Trace/Very Slight redness. Grade 2: Slight/Mild redness. Grade 3: Moderate redness. Grade 4: Severe redness.

+Eligibility

Sex: All, ages: 45 Years to 85 Years

Inclusion Criteria:

Diagnosis of senile cataract with stage 2 or 3 nuclear opalescence according to the - Lens Opacities Classification System III (LOCS-3) grading scale

Exclusion Criteria:

1. Former incisional surgery
2. Former diagnosis of corneal disease
3. Autoimmune diseases
4. Mental diseases

+Locations (1)

FacilityCityCountryStatus
University Hospital of AlexandroupolisAlexandroupoli, EvrosGreece

+Publications

  • Labiris G, Ntonti P, Sideroudi H, Kozobolis V. Impact of polyethylene glycol 400/propylene glycol/hydroxypropyl-guar and 0.1% sodium hyaluronate on postoperative discomfort following cataract extraction surgery: a comparative study. Eye Vis (Lond). 2017 May 10;4:13. doi: 10.1186/s40662-017-0079-5. eCollection 2017. PMID 28497070
  • Ntonti P, Panagiotopoulou EK, Karastatiras G, Breyannis N, Tsironi S, Labiris G. Impact of 0.1% sodium hyaluronate and 0.2% sodium hyaluronate artificial tears on postoperative discomfort following cataract extraction surgery: a comparative study. Eye Vis (Lond). 2019 Feb 11;6:6. doi: 10.1186/s40662-019-0131-8. eCollection 2019. PMID 30805405

+Investigators